Key MessageThis report with long-term follow-up of M1 patients randomised within the STAMPEDE trial's docetaxel comparison confirms a clinically significant benefit associated with the use of upfront docetaxel with androgen deprivation therapy in M1 prostate cancer. It should be a first-line option for fit metastatic hormone-naïve prostate cancer patients regardless of metastatic burden.

Introduction
============

The primary analysis of STAMPEDE's 'docetaxel comparison', reporting an improvement in survival, was triggered by reaching a pre-specified number of control group deaths \[[@mdz396-B1]\]. The trial team agreed to update this analysis when there was a meaningful increase in the number of primary outcome measure events after further follow-up, expected to occur ∼3 years later. During that time, the Intermediate Clinical Endpoints in Cancer of the Prostate surrogacy work showed that measures based on metastatic progression could be used as a surrogate for survival in patients presenting with M0 disease, allowing trials in that setting to achieve increased power sooner \[[@mdz396-B2]\]. Given the prognosis for metastatic and non-metastatic patients is now very different and that other trials of first-line docetaxel have kept metastatic and non-metastatic patients separate, the STAMPEDE team agreed that the long-term follow-up results would be analysed separately for these two groups of patients.

Since that initial STAMPEDE report, first-line systemic combination treatment options given with ADT in metastatic hormone naïve prostate cancer (mHNPC) have expanded to include abiraterone, enzalutamide and apalutamide as well as docetaxel \[[@mdz396-B1], [@mdz396-B3]\]. However there is still controversy about patient stratification and selection for treatment. Metastatic burden sub-group analyses of the CHAARTED and GETUG-15 trials have led some to conclude that docetaxel should not be given as a first-line treatment of patients presenting with 'low metastatic burden' disease \[[@mdz396-B3], [@mdz396-B9]\]. This represents ∼40% of patients presenting with *de novo* mHNPC \[[@mdz396-B12], [@mdz396-B13]\]. These were retrospective analyses of relatively small sub-groups of these trials and a number of groups have not been persuaded by these exploratory retrospective analyses. Reflecting this uncertainty, major treatment guidelines offer conflicting advice about whether all metastatic patients should receive combination treatment or whether this should be restricted only to those with 'high-burden', as specified in the CHAARTED trial \[[@mdz396-B11], [@mdz396-B14]\].

To address the hypothesis raised by CHAARTED, bone scans from the M1 docetaxel comparison cohort were collected retrospectively to determine the metastatic burden for STAMPEDE patients (independently of treatment assignment and outcome) and to undertake a stratified sub-group analysis. Outcome for the sub-groups categorised by individual metastatic burden was then determined using the extended patient follow-up now available in the STAMPEDE M1 cohort.

Materials and methods
=====================

Study design
------------

The multi-arm, multi-stage STAMPEDE trial enrols patients with advanced high-risk or metastatic prostate cancer. Between 05 October 2005 and 31 March 2013, men with newly diagnosed metastatic prostate cancer were randomised on a 2 : 1 basis either to a standard-of-care (SOC) control group ('Control') or SOC + docetaxel treatment group ('docetaxel') \[[@mdz396-B1]\]. SOC in M1 patients comprised long-term androgen deprivation therapy (ADT), the intervention being lifelong ADT and six cycles of docetaxel at standard dose. Randomisation followed a minimisation algorithm with a random element of 20%, stratified for hospital site, age at randomisation (\<70 years old versus ≥70 years old at randomisation), WHO performance status (a score of 0 versus 1/2), nodal involvement (negative, positive or unspecified), planned ADT and usage (yes/no) of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). The randomisation algorithm was developed and maintained centrally at the MRC Clinical Trials Unit at UCL. The trial was carried out in accordance with Good Clinical Practice guidelines, with full regulatory and ethical approval.

The first efficacy results for docetaxel within the STAMPEDE \[[@mdz396-B1]\] used data from the initial randomisation in October 2005 to the data freeze with follow-up to March 2015. The date of this analysis was pre-determined by accumulation of events in the control group. In this paper, we report on a pre-planned long-term efficacy analyses of the M1 patient cohort but with updated results using extended follow-up data to July 2018.

Procedures
----------

All procedures relating to administration and reporting of docetaxel as a research treatment have been reported previously \[[@mdz396-B1]\]. In brief, patients were randomised to lifelong ADT with or without six cycles of docetaxel (75 mg/m^2^) given 3-weekly with prednisolone 5 mg twice daily during the 18-week period of therapy.

The follow-up schedule, defined in the trial protocol, involved follow-up visits every 6 weeks until 6 months after randomisation, then 12 weeks to 2 years, 6 months to 5 years and annually thereafter. Toxicity was reported routinely at follow-up visits. Adverse event classification and grades followed the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Since the primary report for this comparison, data on baseline metastatic burden has been retrospectively collected where possible for UK patients blinded to treatment outcomes. Metastatic burden was assessed using whole-body scintigraphy and computed tomography or magnetic resonance imaging staging scans, categorised following the definition used in the CHAARTED trial \[[@mdz396-B3]\], where high-burden patients had either four or more bone metastases including one or more outside the vertebral body or pelvis, or any visceral metastases, or both. All other patients metastatic at baseline were categorised as having low metastatic burden according to this definition.

Outcomes
--------

Overall survival was specified as the primary efficacy outcome and defined as time from randomisation to death from any cause. Secondary outcomes for long-term efficacy data included: failure-free survival (FFS; time from randomisation to the first of any: biochemical, lymph node, distant metastatic progression or prostate cancer death); progression-free survival (PFS; time from randomisation to the first FFS event, not including biochemical progression); metastatic progression-free survival (mPFS; time from randomisation to either new metastases, progression of existing metastases or prostate cancer death) and prostate cancer-specific survival (PCSS; time from randomisation to prostate cancer death). Biochemical progression was assessed using prostate-specific antigen (PSA) measurements which were reported at each follow-up visit. The lowest PSA value within the first 24 weeks after enrolment was used to define a nadir, from which an increase of 50% and to a minimum level of 4 ng/ml indicated biochemical progression. For a small proportion of patients, PSA levels did not fall after enrolment and a nadir could not be estimated; these patients were considered to have biochemical progression at the date of randomisation. Patients without any event of interest reported by the time of the data freeze were censored in the analyses at the time they were last recorded in the trial as without an event.

The cause of death was assigned as prostate cancer/not prostate cancer where possible, using a set of rules pre-specified by the Trial Management Group's End point Review Committee. Any deaths not meeting the pre-specified rules were individually reviewed by a trial clinician to assign a cause of death independent of the allocated treatment.

Statistical analysis
--------------------

Sample size calculations for trial design used the `nstage` function in Stata, based on a target HR of 0.75 for the primary efficacy analysis. Long-term outcome analysis was planned for ∼3 years after the first analysis, when there was projected to be a 40% increase in control group deaths. For the long-term analysis by metastatic disease burden, there was 66% and 77% power to detect a hazard ratio of 0.75 in the low and high-burden sub-groups, respectively. This calculation used the observed accrual and previous event rate in the control group (without reference to any accumulating differences between arms/sub-groups).

Efficacy analyses, following intention-to-treat principles, included all patients allocated to a trial arm. Toxicity and adverse event data are presented with patients grouped according to whether or not docetaxel treatment was reported as having been started (29 patients randomised to docetaxel who did not receive the drug are reported as Controls for the purposes of comparing toxicity between the treatments). See Figure [1](#mdz396-F1){ref-type="fig"} for full details of patients included in the analyses.

![Consort diagram.](mdz396f1){#mdz396-F1}

All time-to-event analyses followed standard survival analysis methods using Stata (version 15.1). Median duration of follow-up period was estimated using the Kaplan--Meier method with reverse-censoring of any reported deaths. Hazard ratios were estimated from Cox proportional hazards regression models, adjusted for minimisation factors used in the randomisation algorithm (nodal stage, age at randomisation, WHO performance score, use of aspirin/NSAIDs, planned use of SOC radiotherapy) and stratified by time period, as defined according to the other arms open to accrual in STAMPEDE (i.e. changes through closure or opening of other trial arms on the platform) or SOC practice changes. Non-parametric stratified log-rank tests were used to test for differences between the control and docetaxel groups, with stratification the same as that of the Cox regression models. Flexible parametric models were used to generate 5-year survival estimates, fitted using (5,5) degrees of freedom with adjustment variables as specified above. PCSS was analysed using Fine and Grey regression methods for competing risks analysis \[[@mdz396-B17]\]. For all outcomes, models were tested for evidence of non-proportional hazards, and where found, interpretation of the results emphasises restricted mean survival time (RMST), which was calculated using a t\* of 120 months, estimated as described previously \[[@mdz396-B18]\]. For all statistical tests, two-sided tests were used and 95% confidence intervals and *P*-values are reported. Sub-group analyses are presented for all outcomes for metastatic burden sub-groups (low- and high-burden sub-groups). Although our emphasis is on metastatic burden, exploratory sub-group analyses are also presented for the primary outcome in order to give detail on the consistency of treatment effect across baseline factors of potential interest for this patient population: nodal status (N0, N+ or NX), Gleason sum score (≤7, 8--10 or unknown), patient age (\<70 or ≥70) and WHO performance score (0 or 1--2).

Results
=======

One thousand and eighty-six metastatic patients (724 control/362 docetaxel) were recruited to STAMPEDE's 'docetaxel comparison' between 05 October 2005 and 31 March 2013. The dataset for this analysis was frozen on 13 July 2018. As reported previously, baseline patient characteristics were well-balanced across trial arms (Table [1](#mdz396-T1){ref-type="table"}). We additionally report sub-group analyses according to metastatic burden, which was assessed using bone scans available from 830/1086 (76%) of all recruited patients. The patients included in these sub-group analyses were well-balanced across arms (Table [2](#mdz396-T2){ref-type="table"} and [supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). In addition, a comparison of Tables [1](#mdz396-T1){ref-type="table"} and [2](#mdz396-T2){ref-type="table"} demonstrates that the subset of patients included in the metastatic burden sub-group analyses was representative of the metastatic patients in the comparison as a whole, with the exception of the year of randomisation, where the patients included in the metastatic burden sub-group analyses were enrolled in the latter years of recruitment to the comparison. Figure [1](#mdz396-F1){ref-type="fig"} shows a Consort diagram with full details of patient numbers included in the analyses.

###### 

Baseline characteristics for all metastatic patients, by trial arm

  Patient characteristic                                  Control     Docetaxel         
  ------------------------------------------------------- ----------- ----------- ----- ------
  Randomised (2 : 1 allocation)                           724         100%        362   100%
  Age at randomisation (years)                                                          
   Median                                                 65          65                
   IQR                                                    60--71      60--70            
  WHO performance status                                                                
   0                                                      521         72%         270   75%
   1--2                                                   203         28%         92    25%
  T stage                                                                               
   T0                                                     3           \<1%        1     \<1%
   T1                                                     12          2%          0     0%
   T2                                                     75          10%         51    14%
   T3                                                     404         56%         197   54%
   T4                                                     163         23%         82    23%
   TX                                                     67          9%          31    9%
  Nodal status                                                                          
   N0                                                     242         33%         118   33%
   N+                                                     416         57%         211   58%
   NX                                                     66          9%          33    9%
  Metastatic burden[^a^](#tblfn1){ref-type="table-fn"}                                  
   Low                                                    238         33%         124   34%
   High                                                   320         44%         148   41%
   Unassessed                                             166         23%         90    25%
  Site of metastases[^b^](#tblfn2){ref-type="table-fn"}                                 
   Bone                                                   634         88%         307   85%
   Liver                                                  15          2%          6     2%
   Lung                                                   33          5%          13    4%
   Nodes[^c^](#tblfn3){ref-type="table-fn"}               221         31%         102   28%
   Other                                                  46          6%          25    7%
  Gleason sum score                                                                     
   ≤7                                                     158         22%         65    18%
   8--10                                                  480         66%         253   70%
   Unknown                                                86          12%         44    12%
  PSA                                                                                   
   Median                                                 102.5       97                
   IQR                                                    32.8--354   40.5--340         
  Time from diagnosis to randomisation (days)                                           
   Median                                                 69          73                
   IQR                                                    49--92      55--95            
  Planned SOC RT[^d^](#tblfn4){ref-type="table-fn"}                                     
   Not planned                                            677         94%         333   92%
   Planned                                                47          6%          29    8%
  Previously treated                                                                    
   No                                                     689         95%         347   96%
   Yes                                                    35          5%          15    4%
  Pain from prostate cancer                                                             
   Absent                                                 553         76%         270   75%
   Present                                                154         21%         88    24%
   Unknown                                                17          2%          4     1%
  Year of randomisation                                                                 
   2005                                                   1           \<1%        1     \<1%
   2006                                                   28          4%          14    4%
   2007                                                   38          5%          19    5%
   2008                                                   70          10%         34    9%
   2009                                                   93          13%         45    12%
   2010                                                   111         15%         58    16%
   2011                                                   169         23%         87    24%
   2012                                                   172         24%         85    23%
   2013                                                   42          6%          19    5%
  Total                                                   724         100%        362   100%

CHAARTED definition.

Patients may have had more than one site of metastases at baseline, therefore are represented in more than one 'site of metastases' category. Percentages shown are per individual site for the total patients in the arm.

Non-regional lymph nodes.

Primary site RT was not standard-of-care (SOC) for M1 patients at the time of the trial. However, SOC RT was reported as planned for a small proportion of patients due to clinical decisions for these individual cases to receive RT to non-prostate locations, or due to mis-reporting of palliative RT.

###### 

Baseline characteristics, for the subset of 830/1086 patients included in metastatic burden sub-group analysis, by trial arm

  Patient characteristic                                  Control     Docetaxel           
  ------------------------------------------------------- ----------- ------------- ----- ------
  Randomised                                              558         100%          272   100%
  Age at randomisation (years)                                                            
   Median                                                 65          65                  
   IQR                                                    60--71      62--70              
  WHO performance status                                                                  
   0                                                      405         73%           204   75%
   1--2                                                   153         27%           68    25%
  T stage                                                                                 
   T0                                                     1           \<1%          1     \<1%
   T1                                                     9           2%            0     0%
   T2                                                     56          10%           36    13%
   T3                                                     315         56%           155   57%
   T4                                                     129         23%           58    21%
   TX                                                     48          9%            22    8%
  Nodal status                                                                            
   N0                                                     185         33%           88    32%
   N+                                                     322         58%           161   59%
   NX                                                     51          9%            23    8%
  Metastatic burden[^a^](#tblfn5){ref-type="table-fn"}                                    
   Low                                                    238         43%           124   46%
   High                                                   320         57%           148   54%
  Site of metastases[^b^](#tblfn6){ref-type="table-fn"}                                   
   Bone                                                   485         87%           226   83%
   Liver                                                  12          2%            4     1%
   Lung                                                   22          4%            12    4%
   Nodes[^c^](#tblfn7){ref-type="table-fn"}               175         31%           78    29%
   Other                                                  38          7%            20    7%
  Gleason sum score                                                                       
   ≤7                                                     118         21%           51    19%
   8--10                                                  381         68%           188   69%
   Unknown                                                59          11%           33    12%
  PSA                                                                                     
   Median                                                 102.5       96.8                
   IQR                                                    33--338.7   37.8--348.1         
  Time from diagnosis to randomisation (days)                                             
   Median                                                 69          74                  
   IQR                                                    50--92      56--95              
  Planned SOC RT[^d^](#tblfn8){ref-type="table-fn"}                                       
   Not planned                                            523         94%           252   93%
   Planned                                                35          6%            20    7%
  Previously treated                                                                      
   No                                                     528         95%           261   96%
   Yes                                                    30          5%            11    4%
  Pain from prostate cancer                                                               
   Absent                                                 427         77%           200   74%
   Present                                                120         22%           69    25%
   Unknown                                                11          2%            3     1%
  Year of randomisation                                                                   
   2005                                                   0           0%            0     0%
   2006                                                   0           0%            0     0%
   2007                                                   0           0%            0     0%
   2008                                                   19          3%            8     3%
   2009                                                   82          15%           39    14%
   2010                                                   105         19%           52    19%
   2011                                                   157         28%           78    29%
   2012                                                   157         28%           78    29%
   2013                                                   38          7%            17    6%
  Total                                                   558         100%          272   100%

CHAARTED definition.

Patients may have had more than one site of metastases at baseline, therefore are represented in more than one 'site of metastases' category. Percentages shown are per individual site for the total patients in the arm.

Non-regional lymph nodes.

Primary site RT was not standard-of-care (SOC) for M1 patients at the time of the trial. However, SOC RT was reported as planned for a small proportion of patients due to clinical decisions for these individual cases to receive RT to non-prostate locations, or due to mis-reporting of palliative RT.

The median duration of follow-up was 78.2 months (inter-quartile range (IQR): 62.9--96.3). There were 719 deaths reported; 494/724 (68%) control patients died compared with 225/362 (62%) docetaxel patients. Control group patients had a median survival of 43.1 months and an estimated 5-year survival of 37% (95% CI 34% to 41%), whereas patients receiving docetaxel had a median survival of 59.1 months and 5-year survival of 49% (95% CI 44% to 54%). There was good evidence of a benefit from docetaxel on survival (stratified log-rank test *P* = 0.003, HR = 0.81, 95% CI 0.69--0.95; Figure [2](#mdz396-F2){ref-type="fig"}A). As there was evidence (*P* = 0.016) of non-proportional hazards in the treatment effect, the interpretation of these results focuses on the difference in RMST between arms. This method showed evidence of a benefit of docetaxel, with an estimated difference of 6.0 months (95% CI 0.7--11.4) in RMST (over 120 months) between groups.

![Kaplan--Meier curves (solid line) and fitted flexible parametric model estimates (dashed line) for overall survival (left) and failure-free survival (right), by trial arm, for all M1 patients (A,B) low-burden M1 patients (C,D) and high-burden M1 patients (E,F).](mdz396f2){#mdz396-F2}

There was no evidence of heterogeneity of treatment effect on survival over metastatic burden sub-groups (interaction *P* = 0.827). For the low-burden patients (*n* = 362, deaths = 166; Figure [2](#mdz396-F2){ref-type="fig"}C), the median survival in control was 76.7 months, with 5-year survival 57% (95% CI 51% to 64%), compared with a median of 93.2 months and 5-year survival of 72% (95% CI 65% to 80%) for docetaxel. Results for high-burden patients (*n* = 468, deaths = 360) were similar in terms of docetaxel effect, although, as expected, the high-burden patients generally had shorter survival time than low-burden patients (Figure [2](#mdz396-F2){ref-type="fig"}E). The median survival for control was 35.2 months and the 5-year survival estimate of 24% (95% CI 20% to 29%), compared with 39.9 months with a 5-year survival of 34% (95% CI 27% to 42%) for docetaxel. The hazard ratios were consistent in the low-burden (HR = 0.76, 95% CI 0.54--1.07, *P* = 0.107) and high-burden (HR = 0.81, 95% CI 0.64--1.02, *P* = 0.064) sub-groups. The consistency of docetaxel treatment effect on survival across other baseline characteristics was examined as exploratory sub-group analyses, summarised in Figure [3](#mdz396-F3){ref-type="fig"}. There is no good evidence that the docetaxel effect varies across any of the sub-groups included (nodal status, Gleason sum score, age or WHO performance score).

![Effect of docetaxel on overall survival across exploratory sub-groups according to baseline factors.](mdz396f3){#mdz396-F3}

There was good evidence of significant benefit for adding docetaxel on failure-free (HR = 0.66, 95% CI 0.57--0.76, *P* \< 0.001; Figure [2](#mdz396-F2){ref-type="fig"}B), progression-free (HR = 0.69, 95% CI 0.59--0.81, *P* \< 0.001; Figure [4](#mdz396-F4){ref-type="fig"}A), metastatic progression-free (HR = 0.72, 95% CI 0.62--0.84, *P* \< 0.001; Figure [4](#mdz396-F4){ref-type="fig"}B) and PCSS (sub-HR = 0.78, 95% CI 0.66--0.93, *P* = 0.005; Figure [4](#mdz396-F4){ref-type="fig"}C). Furthermore, the effect of treatment was consistent across metastatic burden sub-groups (interaction *P*-values: FFS = 0.792; PFS = 0.855; mPFS = 0.960; PCSS = 0.413) for other outcome measures (Table [3](#mdz396-T3){ref-type="table"}).

![Kaplan--Meier curves (solid line) and fitted flexible parametric model estimates (dashed line), by trial arm, for (A) progression-free survival and (B) metastatic progression-free survival; (C) shows the cumulative incidence function, by trial arm, for prostate cancer death (solid line) and non-prostate cancer death (dashed line).](mdz396f4){#mdz396-F4}

###### 

Hazard ratio (95% CI) from adjusted Cox model, 5-year survival estimates by trial arm from flexible parametric model and restricted mean survival times (RMST) by trial arm, for each outcome measure and each metastatic burden sub-group

                                                                         Hazard ratio (95% CI)   5-year survival   RMST (months)   Interaction by metastatic burden *P*-value                               
  ---------------------------------------------------------------------- ----------------------- ----------------- --------------- -------------------------------------------- ------ -------------------- -------
  Overall survival                                                                                                                                                                                          
   All patients                                                          0.81 (0.69--0.95)       37                49              57.1                                         63.1   6.0 (0.7--11.4)      0.827
   Low-burden                                                            0.76 (0.54--1.07)       57                72              75.8                                         78.8   3.0 (−7.0 to 13.0)   
   High-burden                                                           0.81 (0.64--1.02)       24                34              44.8                                         51.3   6.6 (−0.8 to 14.0)   
  Failure-free survival                                                                                                                                                                                     
   All patients                                                          0.66 (0.57--0.76)       13                21              25.3                                         36.7   11.4 (6.8--16.0)     0.792
   Low-burden                                                            0.63 (0.48--0.82)       22                36              36.8                                         52.3   15.5 (6.2--24.8)     
   High-burden                                                           0.64 (0.51--0.79)       7                 12              18.0                                         26.6   8.5 (2.7--14.4)      
  Progression-free survival                                                                                                                                                                                 
   All patients                                                          0.69 (0.59--0.81)       25                37              40.7                                         53.4   12.8 (7.2--18.3)     0.855
   Low-burden                                                            0.62 (0.45--0.85)       41                56              58.7                                         76.2   17.5 (7.4--27.6)     
   High-burden                                                           0.68 (0.54--0.85)       13                24              27.9                                         40.5   12.6 (5.3--19.8)     
  Metastatic progression-free survival                                                                                                                                                                      
   All patients                                                          0.72 (0.62--0.84)       28                38              44.1                                         55.3   11.2 (5.8--16.6)     0.960
   Low-burden                                                            0.67 (0.48--0.92)       48                61              64.6                                         78.0   13.4 (2.9--23.9)     
   High-burden                                                           0.70 (0.56--0.87)       15                24              29.7                                         41.1   11.4 (3.9--18.9)     
  Prostate cancer-specific survival[^a^](#tblfn9){ref-type="table-fn"}                                                                                                                                      
   All patients                                                          0.78 (0.66--0.93)       41                53              60.3                                         67.9   7.6 (1.9--13.4)      0.413
   Low-burden                                                            0.67 (0.45--0.98)       63                76              80.3                                         88.5   8.2 (−1.5 to 18.0)   
   High-burden                                                           0.84 (0.66--1.07)       27                36              47.1                                         54.6   7.5 (−0.4 to 15.3)   

Competing risks model used to estimate hazard ratios for prostate cancer-specific survival, as described in the Materials and methods section.

Treatment adherence to docetaxel was reported previously \[[@mdz396-B1]\]; all patients had completed docetaxel treatment before the first efficacy analysis. Twenty-nine metastatic patients allocated to Docetaxel never reported starting chemotherapy. They are included in Control for toxicity analysis (see Figure [1](#mdz396-F1){ref-type="fig"}) which is summarised in Table [4](#mdz396-T4){ref-type="table"} and [supplementary Table S2](#sup1){ref-type="supplementary-material"} and [Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online. A comparison of toxicity reported across groups in the first year of follow-up shows higher toxicity in docetaxel (42% docetaxel reported G3-5 toxicity versus 24% in Control). However, toxicity reports for subsequent follow-up, after the initial year, are balanced across groups (27% docetaxel reported G3-5 toxicity compared with 28% control), with no good evidence of increased toxicity in the docetaxel group after the first year of follow-up. Table [5](#mdz396-T5){ref-type="table"} shows some evidence that control patients were more likely to report starting second-line (or subsequent) treatment following disease progression, with 80% reporting starting at least one further line of treatment compared with 68% for Docetaxel. The types of further therapy reported are broadly similar between the two groups.

###### 

Worst adverse event grade reported per patient (across all CTCAE categories) for (i) up to one year on the trial; and (ii) after one year on the trial

  Worst AE grade                              Up to one year[^a^](#tblfn10){ref-type="table-fn"}   After one year[^a^](#tblfn10){ref-type="table-fn"}                                   
  ------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----- ------ ----- ------ ----- ------
  0                                           21                                                   3%                                                   0     0%     26    6%     12    5%
  1                                           267                                                  36%                                                  63    19%    147   32%    65    25%
  2                                           268                                                  36%                                                  128   39%    155   34%    109   43%
  3                                           157                                                  21%                                                  96    29%    110   24%    63    25%
  4                                           20                                                   3%                                                   44    13%    15    3%     6     2%
  5                                           2                                                    \<1%                                                 1     \<1%   1     \<1%   0     0%
  No FU/SAE reported                          18                                                   n/a                                                  1     n/a    18    n/a    1     n/a
  Not on FU after one year                    n/a                                                  n/a                                                  n/a   n/a    281   n/a    77    n/a
  Total[^b^](#tblfn11){ref-type="table-fn"}   753                                                  100%                                                 333   100%   753   100%   333   100%

Timed from randomisation.

Total numbers shown for safety population, where 29 patients allocated to the Docetaxel Group never started Docetaxel treatment and are therefore included in the standard-of-care (SOC) group for safety reporting. Note that 'missing' data refers to patients who did not report AE data after this point (either died or withdrawn from the trial, or not reporting AEs after disease progression as specified in the trial protocol).

###### 

Numbers of patients reporting starting second-line treatment (SLT), by trial arm

                                                                   Control   Docetaxel         
  ---------------------------------------------------------------- --------- ----------- ----- ------
  Randomised                                                       724       100%        362   100%
  Progression reported[^a^](#tblfn12){ref-type="table-fn"}         641       89%         291   80%
  Any SLT reported                                                 578       80%         246   68%
  Life-prolonging treatments[^b^](#tblfn13){ref-type="table-fn"}                               
   Docetaxel                                                       299       52%         49    20%
   Abiraterone                                                     196       34%         91    37%
   Enzalutamide                                                    113       20%         51    20%
   Cabazitaxel                                                     36        6%          29    11%
   Radium-223                                                      36        6%          21    9%
   Other chemotherapy[^c^](#tblfn14){ref-type="table-fn"}          14        2%          12    5%
  Other treatments[^b^](#tblfn13){ref-type="table-fn"}                                         
   Anti-androgens                                                  451       78%         178   72%
   Dexamethasone                                                   132       23%         49    20%
   Zoledronic acid                                                 130       22%         41    17%
   Prednisolone/prednisone                                         97        17%         28    11%
   Stilboestrol                                                    85        15%         41    17%
   Other bisphosphonate[^d^](#tblfn15){ref-type="table-fn"}        16        3%          7     3%
   Strontium                                                       12        2%          2     \<1%

Any progression event, including biochemical progression.

Percentages shown are calculated using the total numbers of patients reporting at least one SLT for the relevant trial arm. Patient numbers only include patients confirmed to have progressed. Note that patients reporting more than one type of second-line treatment will be represented in more than once.

Other chemotherapy, excluding Docetaxel and Cabazitaxel, which are shown separately.

Other bisphosphonate, excluding Zoledronic acid, which is shown separately.

A sensitivity analysis was undertaken without the M1 patients retrospectively found not to have met all of the strict protocol eligibility criteria, mostly concerning a review of baseline blood pressure measurements. Removing these 120 patients (11%) did not change the primary outcome measure results HR = 0.81 (95% CI 0.68--0.96; *P* = 0.013).

Discussion
==========

In this updated long-term analysis, the relative survival benefit for adding docetaxel to ADT in mHNPC confirmed our previous findings. A statistically and clinically significant improvement in survival and a delayed time to metastatic progression was demonstrated with the combination treatment compared with ADT alone. Importantly, this benefit is seen irrespective of metastatic burden, with no evidence of heterogeneity between the low and high metastatic burden sub-groups across any outcome measures. This reinforces the principle that ADT and docetaxel can be considered as an effective first-line treatment option for men with mHNPC regardless of metastatic burden.

Two other trials have also evaluated the combination of docetaxel with ADT over ADT alone in mHNPC. The first trial, GETUG-AFU-15, enrolled 385 patients and reported with median follow-up of 84 months. This showed no clear evidence of improvement in survival by adding docetaxel to ADT over ADT alone (HR = 0.88, 95% CI 0.68--1.14, *P* = 0.3) \[[@mdz396-B19]\]. The second trial, CHAARTED, enrolled 790 patients and reported with median follow-up of 54 months, demonstrating clear evidence of an improvement in survival for adding docetaxel (HR = 0.72, 95% CI 0.59--0.89, *P* = 0.0018) \[[@mdz396-B3], [@mdz396-B9]\]. STAMPEDE is the largest of the 3 trials, enrolling 1086 mHNPC patients and reporting here with median follow-up of 78 months. Our long-term results for these metastatic patients lie between those of GETUG-AFU-15 and CHAARTED and show clear evidence of improved survival associated with the combination of docetaxel + ADT over ADT alone (HR = 0.81, 95% CI 0.69--0.95, *P* = 0.009).

However, in contrast to the CHAARTED and GETUG-15 trials, we found no good evidence in this study of a difference in benefit between the high and low metastatic burden sub-groups for survival and all other outcome measures. Indeed, the point estimate of the benefit for 'low-burden' patients was of 'greater' magnitude than that for the high-burden group. Prior sub-group analysis conducted as part of the CHAARTED and GETUG-15 trials suggested a smaller overall survival benefit associated with the combination of docetaxel + ADT in patients with low metastatic burden compared with high metastatic burden \[[@mdz396-B10]\]. Based on this, docetaxel was recommended by those authors as a first-line option only for high but not low-burden mHNPC \[[@mdz396-B11]\]. That view was not universally accepted and the inherent limitations of the previous sub-group analyses can possibly explain the discordance to our new findings \[[@mdz396-B14]\]. Nearly 25% of the patients enrolled in the other two trials presented with metastatic disease after previous radical treatment. That group of patients has a different natural history to those presenting with *de-novo* M1 disease \[[@mdz396-B20], [@mdz396-B21]\]. Consequently, the low metastatic burden sub-groups in the CHAARTED and the GETUG-15 trials had fewer than 160 *de-novo* mHNPC patients each \[[@mdz396-B10]\]. In our updated report, ∼95% of patients had *de-novo* M1, with a total of 362 patients in the low metastatic burden sub-group. This larger sample size provides a stronger basis for estimating a treatment effect in this sub-group. Furthermore, there was no evidence of a difference in benefit associated with docetaxel with ADT over ADT alone when considering metastatic burden (interaction *P* = 0.827). Based on these findings, the combination of docetaxel with ADT should be a first-line treatment option for newly diagnosed mHNPC patients regardless of metastatic burden.

Our results have to be interpreted in light of more recently-recruited trials. Since the last report, a number of other systemic treatments such as abiraterone, apalutamide and enzalutamide have also shown statistically and clinically significant survival benefits over SOC alone when used as first-line agents in mHNPC \[[@mdz396-B4]\]. None of the trials using androgen receptor pathway targeting have shown any evidence of heterogeneity of effect by metastatic burden. Our previous analysis of patients randomised contemporaneously within STAMPEDE to a docetaxel group or an abiraterone group did not show any difference in overall survival. Whilst that was acknowledged as under-powered, opportunistic comparison, it remains the only direct randomised comparison of docetaxel and abiraterone, and the results are in keeping with both agents being valid first-line options when combined with ADT \[[@mdz396-B22]\].

Conclusion
==========

This updated report, with long-term follow-up and metastatic burden sub-group analysis, reinforces the benefits of adding docetaxel to ADT in mHNPC. The combination treatment prolongs survival and improves a range of outcome measures, including time to metastatic progression and subsequent therapy. It should be considered as a first-line option for fit patients with mHNPC, irrespective of metastatic burden.

Supplementary Material
======================

###### 

Click here for additional data file.
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